25 Posts Not to Miss from ESMO Congress 2026: Day 4
DeLLphi-304 Trial: Tarlatamab Versus Chemotherapy in SCLC
OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition Part 2
OptiTROP-Breast01 Final Analysis: Sacituzumab Tirumotecan Sustains Overall Survival Benefit in Previously Treated Metastatic Triple-Negative Breast Cancer
Gilberto Lopes: Key Insights from ESMO 2026
Julie Gralow։ ESMO - ASCO Joint Session Explored the Evolving Definition of the Modern Oncologist
Toufic Kachaamy: Neoadjuvant Immunotherapy is Changing Colorectal Cancer Care
Amol Akhade: An Indian Phase III Trial With the Potential to Change Practice in Oral Cavity Cancer
OncoDaily Breast is OncoDaily’s dedicated platform for breast cancer, covering the rapidly evolving landscape of breast oncology. It focuses on the full spectrum of breast malignancies, including hormone receptor-positive/HER2-negative, HER2-positive, triple-negative, and other molecular subtypes. Through OncoDaily Breast, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in breast cancer.
